The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has granted 'in principle' approval to Bharat Biotech for conduct of 'Phase III superiority study and Phase III booster dose study' trials for its intranasal COVID-19 vaccine, reported news agency ANI.
Earlier in mid-December, the company sought permission to conduct clinical trials for its intranasal booster dose.
Bharat Biotech aims to conduct clinical trials on 5,000 subjects (50 per cent vaccinated with Covishield and 50 per cent vaccinated with Covaxin).
Bharat Biotech also manufactures the COVID-19 vaccine Covaxin, which was recently given emergency use authorisation for 12-18 year olds.
Raigad News: Pune History-Sheeter Held For Killing Friend By Pushing Him Into Kal River
Maharashtra Govt Grants Agriculture Status To Fisheries; Guidelines And Credit Schemes In Pipeline
Ghatkopar Drunk Driving Incident: Injured Man Succumbs To Injuries At Rajawadi Hospital
Asia Cup 2025: Check Out The Points Table For Groups A And B
(With inputs from Agencies)
